Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Impact Uses Cyclia Platform to Validate Targetivity of Oncology Candidates

publication date: Sep 23, 2021

Impact Therapeutics of Nanjing will collaborate with Toronto's Cyclia. using Cyclia's Ligand Express data-based platform to assess the "targetivity" of their novel oncology candidates. Impact said the insights gained from the partnership will improve and validate its assets, which are based on synthetic lethality. The company has developed a portfolio of DNA damage response candidates using its in-house discovery work and is expanding to other novel targets. Impact's lead drug is a clinical stage PARP inhibitor that it has partnered with Shanghai's Junshi Biopharma. More details....

Stock Symbol: (HK: 1877; SHA: 688180)

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.